CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (8,794,605)	$ (3,408,448)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	224,753	74,618
Stock-based compensation expense	621,427	451,276
Amortization of premiums and discounts	15,111	60,087
Changes in operating assets and liabilities:
Accounts receivable	(2,613,670)	499,418
Inventories	(644,961)	294,873
Prepaid expenses and other current assets	710,206	(204,098)
Deferred costs	(169,259)	(147,108)
Other assets	(17)	(11,844)
Accounts payable	(1,144,516)	307,521
Accrued expenses and other current liabilities	(939,596)	(1,155,935)
Deferred revenue	5,774,239	(803,503)
Net cash used in operating activities	(6,960,888)	(4,043,143)
Cash flows from investing activities:
Purchases of equipment, molds, furniture and fixtures	(128,701)	(763,600)
Additions to patent rights	(42,259)	(38,100)
Proceeds from maturities of investment securities	6,000,000
Purchases of investment securities		(9,118,161)
Net cash provided by (used in) investing activities	5,829,040	(9,919,861)
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants	1,236,935	103,069
Taxes paid related to net share settlement of equity awards	(115,123)	(104,329)
Net cash provided by (used in) financing activities	1,121,812	(1,260)
Effect of exchange rate changes on cash and cash equivalents	250	(6,745)
Net decrease in cash and cash equivalents	(9,786)	(13,971,009)
Cash and cash equivalents:
Beginning of period	39,067,236	52,097,064
End of period	39,057,450	38,126,055
Noncash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	739,713
Additions to patent rights recorded in accounts payable and accrued expenses	$ 771,100